The GLP is committed to full transparency. Download and review our 2019 Annual Report

Bayer sells animal health division for $7.6 billion, denies deal prompted by glyphosate-cancer lawsuits

| | August 21, 2019
s reutersmedia net
Image: Reuters
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Agriculture and pharmaceutical giant Bayer [August 20] agreed [to] a $7.6 billion deal to sell its animal health business to U.S.-based animal health company Elanco …. The deal with Elanco means Bayer will now no longer make products that prevent and treat diseases in farm animals and pets.

Bayer finds itself in a tough political situation after its $63 billion acquisition of glyphosate-maker Monsanto last year. Having taken on the liability for the controversial weedkiller, Bayer has been facing a wave of claims from plaintiffs saying glyphosate caused their cancer …. Bayer …. denied any link between the glyphosate lawsuits and the animal health sell-off.

Related article:  Addressing all farmers' challenges: Taking ideology out of the glyphosate and 'superweed' debate

Read full, original article: Bayer sells animal health business (Behind paywall)

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend